Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 82024L103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 | 15.3% |
8/14/2026
Event 6/30/2026
|
|
|
Redmile Group, LLC
13D/A
Amendment 6
|
9.9% |
7/17/2026
Event 7/15/2026
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments II, L.P. | 8.1% | ||
|
Deep Track Capital, LP
13G
|
5.2% |
6/17/2026
Event 6/10/2026
|
|
| Deep Track Capital, LP | 5.2% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 5.2% | ||
| David Kroin | 5.2% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 1
|
10.0% |
6/15/2026
Event 6/11/2026
|
|
| Orbimed Advisors LLC | 10.0% | ||
| OrbiMed Capital GP IX LLC | 8.3% | ||
| OrbiMed Genesis GP LLC | 1.7% | ||
|
Redmile Group, LLC
13D/A
Amendment 5
|
9.9% |
6/11/2026
Event 6/9/2026
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments II, L.P. | 6.2% | ||
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 | 13.8% |
5/15/2026
Event 3/31/2026
|
|
| T. Rowe Price Investment Management, Inc. 13G | 11.7% |
2/6/2026
Event 1/31/2026
|
|
|
Prosight Management, LP
13G/A
Amendment 3
|
9.9% |
11/13/2025
Event 9/30/2025
|
|
| Prosight Management, LP | 9.9% | ||
| Prosight Fund, LP | 0.9% | ||
| Prosight Plus Fund, LP | 4.9% | ||
| Prosight Partners, LLC | 9.9% | ||
| W. Lawrence Hawkins | 9.9% | ||
|
Orbimed Advisors LLC
13D
|
10.0% |
9/2/2025
Event 8/25/2025
|
|
| Orbimed Advisors LLC | 10.0% | ||
| OrbiMed Capital GP IX LLC | 8.3% | ||
| OrbiMed Genesis GP LLC | 1.7% | ||
|
Redmile Group, LLC
13D/A
Amendment 4
|
9.9% |
8/26/2025
Event 8/25/2025
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments II, L.P. | 6.4% | ||
|
Redmile Group, LLC
13D/A
Amendment 3
|
11.8% |
8/6/2025
Event 8/4/2025
|
|
| Redmile Group, LLC | 11.8% | ||
| Jeremy C. Green | 11.8% | ||
| Redmile Biopharma Investments II, L.P. | 7.0% | ||
| Vanguard Group Inc 13G/A Amendment 2 | 4.5% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 1.8% |
7/16/2025
Event 6/30/2025
|
|
|
Adage Capital Partners GP, L.L.C.
13G/A
Amendment 1
|
9.8% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 9.8% | ||
| Adage Capital Partners GP, L.L.C. | 0% | ||
| Robert Atchinson | 9.8% | ||
| Phillip Gross | 9.8% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 176 k | $641 k |
| 2026 Q2 | 107 | 83.8 M | $582 M |
| 2026 Q1 | 84 | 56.1 M | $360 M |
| 2025 Q4 | 66 | 42.5 M | $155 M |
| 2025 Q3 | 58 | 36.4 M | $87.0 M |
| 2025 Q2 | 64 | 28.7 M | $22.7 M |
| 2025 Q1 | 76 | 31.2 M | $29.6 M |
| 2024 Q4 | 76 | 31.6 M | $38.3 M |
| 2024 Q3 | 82 | 36.3 M | $125 M |
| 2024 Q2 | 80 | 34.4 M | $133 M |
| 2024 Q1 | 79 | 31.7 M | $283 M |
| 2023 Q4 | 69 | 29.2 M | $208 M |
| 2023 Q3 | 44 | 19.9 M | $30.2 M |
| 2023 Q2 | 44 | 20.1 M | $62.6 M |
| 2023 Q1 | 52 | 20.4 M | $59.8 M |
| 2022 Q4 | 52 | 20.6 M | $47.4 M |
| 2022 Q3 | 65 | 20.7 M | $56.0 M |
| 2022 Q2 | 74 | 21.4 M | $87.0 M |
| 2022 Q1 | 79 | 24.0 M | $102 M |
| 2021 Q4 | 84 | 24.2 M | $210 M |
| 2021 Q3 | 71 | 25.8 M | $525 M |
| 2021 Q2 | 68 | 25.9 M | $750 M |
| 2021 Q1 | 57 | 23.4 M | $683 M |
| 2020 Q4 | 60 | 22.7 M | $1.17 B |